NYSE · Healthcare
Enovis CORP (ENOV)
As-reported financials and recent SEC filings for Enovis CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.25B
Net income
$-1.18B
Net margin
-52.7%
Diluted EPS
$-20.75
ROE
-79.4%
P/E (TTM)
—
Market cap
$1.31B
Debt / equity
0.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.25B | $2.11B | $1.71B | $1.56B | $1.43B |
| Gross profit | $1.35B | $1.18B | $990.8M | $869.4M | $777.7M |
| Operating income | $-1.12B | $-775.7M | $-65.7M | $-71.2M | $-62.8M |
| Net income | $-1.18B | $-825.5M | $-33.3M | $-13.3M | $71.7M |
| Diluted EPS | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.40 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
11-K2026-06-26
View on EDGAR →42026-06-16
View on EDGAR →4/A2026-06-16
View on EDGAR →42026-06-15
View on EDGAR →42026-06-11
View on EDGAR →42026-06-03
View on EDGAR →SD2026-05-28
View on EDGAR →42026-05-21
View on EDGAR →Go deeper on ENOV
Search Enovis CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.